Revive Therapeutics Expands Investment Opportunities
Revive Therapeutics Ltd. (CSE: RVV) has just announced a significant development in its financial strategies. The company has decided to extend its proposed private placement offering, allowing investors to participate in funding its innovative therapeutic initiatives. This offering aims to raise up to $650,000 by issuing a total of 30,952,381 units, offered at a price of $0.021 each.
Details of the Private Placement
Currently, Revive has already completed a first tranche, issuing 2,900,000 units in August, resulting in gross proceeds of $60,900. This additional investment will enable the firm to close another tranche valued at $589,000. Each unit in the offering will include one common share and an accompanying warrant, giving investors the right to acquire additional shares at an exercise price of $0.05, valid for a period of 36 months following the initial closing.
Strategic Use of Funds
The funds procured from this private placement will be directed towards working capital and settling certain trade payables. Revive Therapeutics is optimistic about these financial maneuvers, which are designed to strengthen its operational capacity and support its cutting-edge research and development activities.
Closing Conditions
The completion of the private placement is contingent upon customary closing conditions. Revive's management is dedicated to finalizing the transaction as swiftly as possible, acknowledging the favorable market conditions and the prospective benefits of the funding. All securities issued will be subject to a four-month and one-day hold period.
About Revive Therapeutics Ltd.
Revive Therapeutics is a forward-thinking life sciences company focused on developing groundbreaking therapeutics to address critical medical needs. The company is currently channeling its resources towards the potential of Bucillamine for infectious diseases and has innovative therapies that tackle nerve agent exposure risks. Additionally, Revive is advancing research into Psilocybin and molecular hydrogen, exploring exciting new possibilities in the medical sector.
Regulatory Advantages
By emphasizing the utilization of FDA regulatory incentives such as Emergency Use Authorization and Breakthrough Therapy designations, Revive strategically positions itself for quick advancement and market entry. This strategic positioning enhances its potential to rapidly develop essential treatments and therapies.
Contact Information
For further inquiries or detailed insights about Revive Therapeutics and its ongoing developments, please reach out to:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Frequently Asked Questions
What is the purpose of Revive Therapeutics' private placement?
The private placement aims to raise funds for working capital and payment of trade payables while advancing its innovative therapeutic programs.
What will investors receive in the private placement?
Each unit consists of one common share of the company and one warrant, allowing investors to acquire additional shares at a specified price.
How much capital does Revive Therapeutics intend to raise?
The company aims to raise up to $650,000 through this private placement initiative.
What innovative therapies is Revive Therapeutics focusing on?
Revive is working on Bucillamine for infectious diseases, Psilocybin, and molecular hydrogen therapies.
Who can be contacted for more information on Revive Therapeutics?
Michael Frank, the CEO of Revive Therapeutics, is the primary contact for further insights and queries.
